NCT05656131 2026-03-17
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Suspended
Clinical Trials
12 trialsNCT07353437 2026-01-20
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)
Fudan University
Phase 2 Not yet recruiting
NCT06255392 2025-08-15
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06561022 2024-08-19
abemaSNF1/3
Fudan University
Phase 2 Not yet recruiting
NCT06254066 2024-02-12
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05928780 2023-07-03
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Fudan University
Phase 1/2 Unknown
NCT05761470 2023-03-09
IMPARP
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Recruiting
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown